NasdaqGS:CNTABiotechs
A Look At Centessa Pharmaceuticals (CNTA) Valuation After New Orexin Pipeline And Pre Commercial Plans
Centessa Pharmaceuticals (CNTA) has drawn fresh attention after outlining 2026 plans for its orexin pipeline, including moving lead asset ORX750 toward registrational studies and advancing ORX142 into clinical trials, while also preparing for a pre-commercial shift.
See our latest analysis for Centessa Pharmaceuticals.
The recent orexin updates come after a mixed price pattern, with a 1 month share price return of 11.86% and a 3 month share price return decline of 10.5%. However, the 3 year...